Amylyx Pharmaceuticals, Inc. (AMLX) Misses Q2 EPS by 34c

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) reported Q2 EPS of ($1.07), $0.34 worse than the analyst estimate of ($0.73).

For earnings history and earnings-related data on Amylyx Pharmaceuticals, Inc. (AMLX) click here.

You May Also Be Interested In

• Anthropic Signs $35b Cloud Deal With Lambda In Texas: WSJ
• Veritas Capital To Buy Bodycote For 940 Pence Per Share Value
• HSBC Upgrades Merck KGaA (MRK:GR) (MKGAF) to Buy